Ridogrel

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H318662

CAS#: 110140-89-1

Description: Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin.


Chemical Structure

img
Ridogrel
CAS# 110140-89-1

Theoretical Analysis

Hodoodo Cat#: H318662
Name: Ridogrel
CAS#: 110140-89-1
Chemical Formula: C18H17F3N2O3
Exact Mass: 366.12
Molecular Weight: 366.334
Elemental Analysis: C, 59.02; H, 4.68; F, 15.56; N, 7.65; O, 13.10

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ridogrel, R 68070; R-68070; R68070; R 70416; R-70416; R70416;

IUPAC/Chemical Name: 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid

InChi Key: GLLPUTYLZIKEGF-HAVVHWLPSA-N

InChi Code: InChI=1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17+

SMILES Code: O=C(O)CCCCO/N=C(C1=CC=CN=C1)\C2=CC=CC(C(F)(F)F)=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 366.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Tytgat GN, Van Nueten L, Van De Velde I, Joslyn A, Hanauer SB. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002 Jan;16(1):87-99. PubMed PMID: 11856082.

2: Carty E, Rampton DS, Schneider H, Rutgeerts P, Wright JP. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease. Aliment Pharmacol Ther. 2001 Sep;15(9):1323-9. PubMed PMID: 11552902.

3: Naran NH, Chetty N. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects. Thromb Res. 1997 Dec 1;88(5):399-407. PubMed PMID: 9556227.

4: van der Wieken LR, Simoons ML, Laarman GJ, Van den Brand M, Nijssen KM, Dellborg M, Hermens W, Vrolik W. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction. Int J Cardiol. 1995 Nov 24;52(2):125-34. PubMed PMID: 8749872.

5: Keith JC Jr, Endo Y, Warwick K, Keith KE, Brugh S, Rowles TK. Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension. Prostaglandins. 1994 Mar;47(3):247-63. PubMed PMID: 8016393.

6: Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation. 1994 Feb;89(2):588-95. PubMed PMID: 8313547.

7: Keith JC Jr, Goodrich JA, Endo Y, Taub D, Mehlman P, Ward G. Effects of ridogrel on the prostacyclin-thromboxane ratio in nulliparous third trimester-pregnant rhesus monkeys. Prostaglandins. 1993 Jun;45(6):547-55. PubMed PMID: 8337414.

8: Vanden Bossche H, Willemsens G, Bellens D, Janssen PA. Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis. Biochem Pharmacol. 1992 Feb 18;43(4):739-44. PubMed PMID: 1540227.

9: Di Perri T, Notari M, Assogna G. [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile]. Recenti Prog Med. 1991 Oct;82(10):533-40. Italian. PubMed PMID: 1759039.

10: Janssens WJ, Cools FJ, Hoskens LA, Van Nueten JM. Effect of ridogrel on vascular contractions caused by vasoactive substances released during platelet activation. Thromb Haemost. 1990 Aug 13;64(1):91-6. PubMed PMID: 2148850.

11: Auwerda JJ, Zijlstra FJ, Tak CJ, van den Ingh HF, Wilson JH, Ouwendijk RJ. Ridogrel enemas in distal ulcerative colitis. Eur J Gastroenterol Hepatol. 2001 Apr;13(4):397-400. PubMed PMID: 11338069.

12: Carty E, Macey M, McCartney SA, Rampton DS. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther. 2000 Jun;14(6):807-17. PubMed PMID: 10848666.

13: Ridogrel. R 68070. Drugs R D. 1999 Mar;1(3):270-2. PubMed PMID: 10566044.

14: Schneider TJ, Struijk PC, Wallenburg HC. Placental transfer of the thromboxane synthetase inhibitor ridogrel in the late-pregnant ewe. Eur J Obstet Gynecol Reprod Biol. 1999 Sep;86(1):83-7. PubMed PMID: 10471147.

15: Quest DW, Wilson TW. Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat. Jpn J Pharmacol. 1998 Dec;78(4):479-86. PubMed PMID: 9920205.

16: Heinisch G, Holzer W, Kunz F, Langer T, Lukavsky P, Pechlaner C, Weissenberger H. On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel. J Med Chem. 1996 Sep 27;39(20):4058-64. PubMed PMID: 8831771.

17: Tranchesi B, Pileggi F, Vercammen E, Van de Werf F, Verstraete M. Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin. Eur Heart J. 1994 May;15(5):660-4. PubMed PMID: 8056007.

18: Hoet B, Arnout J, Deckmyn H, Vermylen J. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor. Thromb Haemost. 1993 Nov 15;70(5):822-5. PubMed PMID: 8128441.

19: De Cree J, Geukens H, Gutwirth P, De Clerck F, Vercammen E, Verhaegen H. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication. Int Angiol. 1993 Mar;12(1):59-68. PubMed PMID: 8376914.

20: Weber C, Beetens JR, Tegtmeier F, Van Rooy P, Vercammen E, Wouters L, De Clerck F. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man. Thromb Haemost. 1992 Aug 3;68(2):214-20. PubMed PMID: 1412169.